Sanjay Lakhotia is the Chief Business Officer with responsibilities that include partnering, product development strategy, and clinical development. Dr. Lakhotia has over 25 years’ experience in corporate development, product development and strategy at leading biotech and pharmaceutical companies. Between 2010 and 2013, Sanjay led corporate development at Pathway Therapeutics, a clinical stage cancer and autoimmune company. Prior to Pathway, Sanjay was senior director of corporate development at Portola Pharmaceuticals, where his responsibilities included product licensing and program leadership. While at Portola, Sanjay contributed to the partnering of a significant Phase 2 asset and championed the development of an important cardiovascular drug now in registration with breakthrough therapy status.
Prior to joining Portola in 2006, Sanjay held corporate development positions of increasing responsibilities at Onyx Pharmaceuticals and MedImmune where he led the execution of several product and technology licensing transactions. Before transitioning to corporate development, Sanjay led process development groups at Wyeth Pharmaceuticals and Baxter contributing to the development of important vaccines, Prevnar and Meningetec. Sanjay obtained his Ph.D. in Biochemical Engineering at Northwestern University, an MBA from University of North Carolina, Chapel Hill, and BS in chemical engineering from the University of California, Berkeley.
Brad Cann has more than 19 years of financial and business experience. Between 2004 and 2009, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust (REIT), a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second largest hotel REIT. Brad joined Royal Host in January 2004 and held a number of senior positions and was appointed Chief Financial Officer in May 2007 and Executive Vice President in January 2008. Brad's responsibilities included financial reporting, accounting, taxation, investor relations, payroll, information technology and internal audit. As acting Co-Chief Executive Officer of Royal Host, Brad shared responsibility for developing the strategic initiatives of the Trust and leading its executive team in day-to-day operations, as well as investing, financing and real estate transactions.
Prior to joining Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company and Chief Financial Officer of an oilfield waste water treatment company. Prior thereto, Brad held various positions with a chartered accounting firm.
Henrik Hansen has more than 15 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include medicinal chemistry, carbohydrate chemistry, high throughput synthesis, process development, and manufacturing of drug substances and drug products under Good Manufacturing Practices (GMPs) for clinical use.
Henrik has held a number of positions within Zenith and am currently Senior Vice President of Operations with responsibility for Project Management, Intellectual Property, CMC, Quality Assurance, and the Medicinal Chemistry Program.
Henrik holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 40 articles and meeting abstracts and is listed as an inventor of 9 patent families.
Edward van der Horst is the Vice President of Discovery Research and Preclinical Development. He has worked with small molecules, antibodies, and antibody-drug conjugates during his 16 years in the biotechnology industry and has extensive experience in target discovery, selection and validation in the oncology and immuno-oncology space.
Prior to joining Zenith, Edward spearheaded the preclinical drug development efforts at Igenica Biopharmaceuticals Inc. which resulted in the successful acquisition of immuno-oncology assets by Pierre Fabre. Previously, his contributions and discoveries have led to the development and clinical evaluation of various antibodies at OncoMed Pharmaceuticals, as well as to the first clinical stage anti-HER3 antibody at U3 Pharma GmbH (acquired by Daiichi-Sankyo).
Edward studied chemistry at the Heinrich-Heine University, Düsseldorf and the Ludwig-Maximilian University of Munich, conducted his master’s thesis at the Max-Planck Institute of Neurobiology and received his Ph.D. in biochemistry from the Max-Planck Institute of Biochemistry in the lab of Prof. Axel Ullrich. Edward completed his postdoctoral training at Tularik, Inc (acquired by Amgen).